RxDoctor Payments Data

Richard Lucarelli, MD

Interventional Pain Medicine · Vernon, CTNPI 1205179462

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $51,385 of the $71,075 with a category attached, or 72.3%. Genentech USA, Inc. accounts for 95.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $49,757 and has fallen 97.2% since, to $1,407 in 2025.

$71,075in general payments, 2019–2025

Across 134 payments — averaging $530.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$68K
  • Medtronic$1K
  • SPR Therapeutics, Inc$1K
  • Boston Scientific$259
  • Saluda Medical Americas, Inc.$98
  • Si-bone, Inc.$91
  • plus $35 from 1 others

What the payments were for

  • Consulting fees$3,7205%
  • Speaking & faculty fees$51,38572%
  • Travel & lodging$12,69918%
  • Food & beverage$3,2715%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$15,195
Medicare patients
34
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine13$3,134
Duloxetine Hcl89$1,368
Pregabalin27$729
Gabapentin42$506
Methocarbamol30$355
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$329
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$268
Cyclobenzaprine Hcl20$186
Nortriptyline Hcl21$163
Meloxicam11$28

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Vernon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →